ES2654908T8 - Análogos de tiazolidindiona para el tratamiento de enfermedades mediadas por una inflamación metabólica - Google Patents
Análogos de tiazolidindiona para el tratamiento de enfermedades mediadas por una inflamación metabólica Download PDFInfo
- Publication number
- ES2654908T8 ES2654908T8 ES15151582.2T ES15151582T ES2654908T8 ES 2654908 T8 ES2654908 T8 ES 2654908T8 ES 15151582 T ES15151582 T ES 15151582T ES 2654908 T8 ES2654908 T8 ES 2654908T8
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- diseases mediated
- metabolic inflammation
- thiazolidinedione analogues
- thiazolidinedione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78289406P | 2006-03-16 | 2006-03-16 | |
US782894P | 2006-03-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2654908T3 ES2654908T3 (es) | 2018-02-15 |
ES2654908T8 true ES2654908T8 (es) | 2018-04-11 |
Family
ID=38328199
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES15151582.2T Active ES2654908T3 (es) | 2006-03-16 | 2007-03-14 | Análogos de tiazolidindiona para el tratamiento de enfermedades mediadas por una inflamación metabólica |
ES07752982T Active ES2397944T3 (es) | 2006-03-16 | 2007-03-14 | Análogos de tiazolidindiona |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES07752982T Active ES2397944T3 (es) | 2006-03-16 | 2007-03-14 | Análogos de tiazolidindiona |
Country Status (15)
Country | Link |
---|---|
US (4) | US20090143442A1 (es) |
EP (3) | EP2486926A1 (es) |
JP (2) | JP5269758B2 (es) |
KR (1) | KR101475955B1 (es) |
CN (1) | CN101454005B (es) |
AU (1) | AU2007227581B2 (es) |
CA (1) | CA2646207C (es) |
ES (2) | ES2654908T3 (es) |
HU (1) | HUE035314T2 (es) |
MX (2) | MX356584B (es) |
NZ (1) | NZ571871A (es) |
PL (2) | PL2001468T3 (es) |
RU (1) | RU2445957C2 (es) |
UA (1) | UA96441C2 (es) |
WO (1) | WO2007109024A2 (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101454006B (zh) | 2006-03-16 | 2012-12-26 | 新陈代谢解决方案开发公司 | 用于治疗高血压以及用于降低血脂的噻唑烷二酮类似物 |
WO2007109088A2 (en) * | 2006-03-16 | 2007-09-27 | Metabolic Solutions Development Company | Combinationtherapies of thiazolidinedione analogues and glucocorticoid agonists |
AU2007227581B2 (en) | 2006-03-16 | 2012-11-08 | Metabolic Solutions Development Company, Llc | Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease |
RU2486179C2 (ru) | 2007-09-14 | 2013-06-27 | МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи | Аналоги тиазолидиндиона для лечения диабета и дислипидемии |
US8304441B2 (en) | 2007-09-14 | 2012-11-06 | Metabolic Solutions Development Company, Llc | Thiazolidinedione analogues for the treatment of metabolic diseases |
US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
PE20151924A1 (es) | 2008-08-12 | 2016-01-13 | Zinfandel Pharmaceuticals Inc | Metodo de identificacion de factores de riesgo de la enfermedad |
CN102753539B (zh) | 2009-12-15 | 2015-09-09 | 新陈代谢解决方案开发公司 | 治疗代谢性疾病的ppar-节制的噻唑烷二酮盐 |
MX2012006744A (es) * | 2009-12-15 | 2012-07-30 | Metabolic Solutions Dev Co Llc | Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas. |
AU2014202074B2 (en) * | 2009-12-15 | 2016-01-07 | Cirius Therapeutics, Inc. | PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
DK2512470T3 (en) * | 2009-12-15 | 2017-02-27 | Octeta Therapeutics Llc | PPAR SAVING THIAZOLIDE INDIA AND COMBINATIONS TO TREAT NEURODEGENERATIVE DISEASES |
GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
GB2477743A (en) * | 2010-02-10 | 2011-08-17 | Argenta Therapeutics Ltd | Enantiomers of 5-methyl-thiazolidine-2,4-dione glitazone compounds |
HUE030263T2 (en) | 2010-04-19 | 2017-04-28 | Octeta Therapeutics Llc | New synthesis for the preparation of thiazolidinedione compounds |
CA2796872A1 (en) * | 2010-04-19 | 2011-10-27 | Metabolic Solutions Development Company, Llc | Novel synthesis for thiazolidinedione compounds |
PL2603507T3 (pl) * | 2010-08-10 | 2016-12-30 | Synteza związków tiazolidynodionu | |
EP2603498B1 (en) | 2010-08-10 | 2016-11-09 | Octeta Therapeutics, LLC | Novel synthesis for thiazolidinedione compounds |
KR20180050420A (ko) | 2011-01-10 | 2018-05-14 | 진판델 파마슈티컬스 인코포레이티드 | 알츠하이머 병 치료를 위한 방법 및 약품 |
WO2012114204A2 (en) * | 2011-02-15 | 2012-08-30 | Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto | Methods of treating mitochondrial dysfunction |
WO2012149083A1 (en) * | 2011-04-28 | 2012-11-01 | Metabolic Solutions Development Company, Llc | Ppar-sparing thiazolidinediones for the treatment of kidney related diseases |
KR20130015932A (ko) * | 2011-08-05 | 2013-02-14 | 연세대학교 산학협력단 | 저용량의 치아졸리딘다이온을 포함하는 알츠하이머 병 치료용 약학조성물 |
KR101501375B1 (ko) | 2012-09-21 | 2015-03-10 | 가톨릭대학교 산학협력단 | 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물 |
WO2014046474A2 (ko) * | 2012-09-21 | 2014-03-27 | 가톨릭대학교 산학협력단 | 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물 |
CA2894653A1 (en) * | 2012-12-11 | 2014-06-19 | Metabolic Solutions Development Company, Llc | Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
AU2014236510A1 (en) | 2013-03-14 | 2015-09-24 | Deuterx, Llc | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
JP6498195B2 (ja) | 2013-07-22 | 2019-04-10 | メタボリック ソリューションズ ディベロップメント カンパニー, エルエルシー | 代謝疾患を処置するためのppar節約化合物 |
ES2831326T3 (es) | 2014-01-15 | 2021-06-08 | Poxel Sa | Métodos para tratar trastornos neurológicos, metabólicos y otros mediante el uso de pioglitazona enantiopura enriquecida con deuterio |
DK3388064T3 (da) * | 2014-04-02 | 2021-04-19 | Minoryx Therapeutics S L | 2,4-thiazolidindionderivater i behandling af forstyrrelse i centralnervesystemet |
BR112019011334A2 (pt) | 2016-12-01 | 2019-10-15 | Minoryx Therapeutics S L | uso de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona e seus sais |
US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
GB202210503D0 (en) | 2022-07-18 | 2022-08-31 | Univ Court Univ Of Glasgow | Materials and methods for treatment of chronic myeloid leukemia (CML) |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5522636A (en) | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
US4582839A (en) * | 1984-03-21 | 1986-04-15 | Takeda Chemical Industries, Ltd. | 2,4-thiazolidinediones |
WO1985004170A1 (en) * | 1984-03-21 | 1985-09-26 | Takeda Chemical Industries, Ltd. | Thiazolidinedione derivatives, process for their preparation, and medicinal composition containing same |
WO1986002073A1 (en) | 1984-10-03 | 1986-04-10 | Takeda Chemical Industries, Ltd. | Thiazolidinedione derivatives, process for their preparation, and pharmaceutical composition containing same |
CN1003445B (zh) * | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物,其制备方法和用途 |
AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
US5167228A (en) * | 1987-06-26 | 1992-12-01 | Brigham And Women's Hospital | Assessment and modification of endogenous circadian phase and amplitude |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
ATE202352T1 (de) * | 1991-04-11 | 2001-07-15 | Upjohn Co | Thiazolidindionderivate, herstellung und anwendung |
US5441971A (en) * | 1991-04-11 | 1995-08-15 | The Upjohn Company | Thiazolidinedione derivatives, production and use thereof |
NO302471B1 (no) | 1991-12-26 | 1998-03-09 | Sankyo Co | Tiazolidinforbindelser og farmasöytisk preparat |
US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
CZ283339B6 (cs) * | 1993-09-15 | 1998-03-18 | Sankyo Company Limited | Použití thiazolidinových derivátů pro výrobu léčivého přípravku pro léčení zhoršené tolerance glukosy pro zabránění nebo zpoždění nástupu diabetes mellitus nezávislé na inzulinu |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
TW438587B (en) | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
NZ286920A (en) | 1995-07-03 | 1997-06-24 | Sankyo Co | Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma |
GB0030845D0 (en) * | 2000-12-18 | 2001-01-31 | Smithkline Beecham Plc | Novel treatment |
EP1387843B1 (en) | 2001-04-26 | 2007-02-28 | Zentiva, a.s. | Method for obtaining pioglitazone as an antidiabetic agent |
JPWO2005054213A1 (ja) * | 2003-12-02 | 2007-12-06 | 塩野義製薬株式会社 | ペルオキシソーム増殖活性化受容体アゴニスト活性を有するイソキサゾール誘導体 |
CN101454006B (zh) * | 2006-03-16 | 2012-12-26 | 新陈代谢解决方案开发公司 | 用于治疗高血压以及用于降低血脂的噻唑烷二酮类似物 |
WO2007109088A2 (en) | 2006-03-16 | 2007-09-27 | Metabolic Solutions Development Company | Combinationtherapies of thiazolidinedione analogues and glucocorticoid agonists |
AU2007227581B2 (en) | 2006-03-16 | 2012-11-08 | Metabolic Solutions Development Company, Llc | Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease |
RU2486179C2 (ru) | 2007-09-14 | 2013-06-27 | МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи | Аналоги тиазолидиндиона для лечения диабета и дислипидемии |
-
2007
- 2007-03-14 AU AU2007227581A patent/AU2007227581B2/en not_active Ceased
- 2007-03-14 MX MX2012009905A patent/MX356584B/es unknown
- 2007-03-14 PL PL07752982T patent/PL2001468T3/pl unknown
- 2007-03-14 EP EP12166539A patent/EP2486926A1/en not_active Withdrawn
- 2007-03-14 HU HUE15151582A patent/HUE035314T2/en unknown
- 2007-03-14 CA CA2646207A patent/CA2646207C/en active Active
- 2007-03-14 MX MX2008011871A patent/MX2008011871A/es active IP Right Grant
- 2007-03-14 EP EP15151582.2A patent/EP2902026B1/en active Active
- 2007-03-14 ES ES15151582.2T patent/ES2654908T3/es active Active
- 2007-03-14 EP EP07752982A patent/EP2001468B1/en active Active
- 2007-03-14 WO PCT/US2007/006321 patent/WO2007109024A2/en active Application Filing
- 2007-03-14 NZ NZ571871A patent/NZ571871A/en not_active IP Right Cessation
- 2007-03-14 PL PL15151582T patent/PL2902026T3/pl unknown
- 2007-03-14 ES ES07752982T patent/ES2397944T3/es active Active
- 2007-03-14 CN CN2007800177654A patent/CN101454005B/zh active Active
- 2007-03-14 UA UAA200812193A patent/UA96441C2/ru unknown
- 2007-03-14 RU RU2008140943/15A patent/RU2445957C2/ru active
- 2007-03-14 JP JP2009500436A patent/JP5269758B2/ja not_active Expired - Fee Related
-
2008
- 2008-09-16 US US12/283,811 patent/US20090143442A1/en not_active Abandoned
- 2008-10-15 KR KR1020087025221A patent/KR101475955B1/ko active IP Right Grant
-
2011
- 2011-05-18 US US13/068,708 patent/US8389556B2/en active Active
-
2013
- 2013-01-28 US US13/751,672 patent/US20130203820A1/en not_active Abandoned
- 2013-03-01 JP JP2013040395A patent/JP2013100371A/ja active Pending
-
2014
- 2014-12-30 US US14/585,619 patent/US9155729B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2654908T8 (es) | Análogos de tiazolidindiona para el tratamiento de enfermedades mediadas por una inflamación metabólica | |
CY2020032I1 (el) | Παραγωγα πλευρομουτιλινης για τη θεραπεια ασθενειων που προκαλουνται απο μικροβια | |
CR11019A (es) | 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas | |
BRPI0817096A2 (pt) | análogos de tiazolidinodiona para o tratamento de hipertensão | |
DK2474321T3 (da) | Sammensætninger til behandling af collagenmedierede sygdomme | |
CR10245A (es) | "nuevas combinaciones terapéuticas para el tratamiento de la depresión" | |
BRPI1012116A2 (pt) | composição farmacêutica para o tratamento de doenças cardíacas | |
DK2056842T3 (da) | Modificeret galactosylceramid til behandling af cancerøse sygdomme | |
ES2525801T8 (es) | Composiciones y métodos para la prevención y el tratamiento de enfermedades autoinmunes | |
BRPI0716435A2 (pt) | Compostos para o tratamento de doenças proliferativas | |
IL200368A0 (en) | Treatment of diseases characterized by inflammation | |
PL1874781T3 (pl) | Dihydrotienopirymidyny do leczenia chorób zapalnych | |
BRPI0919004A2 (pt) | composto de multiheteroarila como inibidores de h-pgds e sua utilização para o tratamento de doenças mediadas por prostaglandina d2 | |
BRPI0911577A2 (pt) | derivados espiro-indol para o tratamento de doenças parasíticas. | |
BRPI0914410A2 (pt) | composição de polidesoxirribonucleotídeo injetável para o tratamento de doenças osteoarticulares. | |
BRPI1009783A2 (pt) | compostos para o tratamento de distúrbios metabólicos. | |
BRPI1013245A2 (pt) | "composto para o tratamento de distúrbios metabólicos" | |
FI20095600A (fi) | Koostumus ihosairauksien hoitoa varten | |
ES2399651T8 (es) | Utilización de pasireotida para el tratamiento de la hipoglucemia hiperinsulenémica endógena | |
IL200091A (en) | Kittensan to treat infectious diseases of the nail | |
LTC2066352I2 (lt) | Išsėtinės sklerozės (MS) gydymas kampatu-1H | |
BRPI0914454A2 (pt) | "composição para o tratamento do tecido epitelial" | |
BRPI0912890A2 (pt) | composição farmacêutica para o tratamento de ejaculação precoce | |
BRPI0923377A2 (pt) | Derivados de 1-amino-alquilciclohexano para o tratamento de doenças mediadas por mastócitos | |
ZA200905364B (en) | Treatment of diseases characterized by inflammation |